Tivic Health Systems Inc (TIVC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tivic Health Systems Inc (TIVC) has a cash flow conversion efficiency ratio of -0.453x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.01 Million) by net assets ($11.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TIVC equity to assets ratio to measure how much of total assets are equity-financed.
Tivic Health Systems Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tivic Health Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TIVC operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Tivic Health Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tivic Health Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hotel Fast SSE AB (publ)
ST:MAXENT-B
|
0.027x |
|
ModuLink Inc.
NASDAQ:MDLK
|
0.323x |
|
NO GRAVITY GAMES ZY -10
F:8YX
|
1.244x |
|
CHRISTINA LAKE CANNABIS
F:CLB
|
-0.033x |
|
Pharos Energy plc
LSE:PHAR
|
0.058x |
|
Atomic Minerals Corp
V:ATOM
|
-0.496x |
|
Yangaroo Inc
V:YOO
|
0.540x |
|
Alturas Minerals Corp
V:ALT
|
0.011x |
Annual Cash Flow Conversion Efficiency for Tivic Health Systems Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tivic Health Systems Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see TIVC company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -481.07% |
| 2021-12-31 | $13.27 Million | $-5.61 Million | -0.423x | -116.44% |
| 2020-12-31 | $-1.18 Million | $-3.03 Million | 2.572x | +266.15% |
| 2019-12-31 | $2.37 Million | $-3.67 Million | -1.548x | -- |
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offe… Read more